Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study

NCT06160596 is registered in ClinicalTrials.gov with Cure 51 as lead sponsor.

NCT NCT06160596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06160596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis: A 3 Cohorts Case Control Matched Study
Lead sponsor
Cure 51
Phase
Observational
Overall status
Recruiting
Start date
November 1, 2023
Completion date
May 1, 2028
Enrollment
1,020 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, idh-wildtype, pancreas adenocarcinoma, small-cell lung cancer